Toll Free: 1-888-928-9744

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 163 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2016, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.

Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 2, 22 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 10 and 1 molecules, respectively.

Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 Introduction 5 Retinitis Pigmentosa (Retinitis) Overview 6 Therapeutics Development 7 Retinitis Pigmentosa (Retinitis) - Therapeutics under Development by Companies 9 Retinitis Pigmentosa (Retinitis) - Therapeutics under Investigation by Universities/Institutes 11 Retinitis Pigmentosa (Retinitis) - Pipeline Products Glance 12 Retinitis Pigmentosa (Retinitis) - Products under Development by Companies 15 Retinitis Pigmentosa (Retinitis) - Products under Investigation by Universities/Institutes 17 Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development 18 Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment 47 Drug Profiles 57 Retinitis Pigmentosa (Retinitis) - Dormant Projects 138 Retinitis Pigmentosa (Retinitis) - Discontinued Products 140 Retinitis Pigmentosa (Retinitis) - Product Development Milestones 141 Appendix 156
List of Tables
Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2016 13 Number of Products under Development for Retinitis Pigmentosa (Retinitis) - Comparative Analysis, H2 2016 14 Number of Products under Development by Companies, H2 2016 15 Number of Products under Development by Companies, H2 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2016 17 Comparative Analysis by Late Stage Development, H2 2016 18 Comparative Analysis by Clinical Stage Development, H2 2016 19 Comparative Analysis by Early Stage Development, H2 2016 20 Products under Development by Companies, H2 2016 21 Products under Development by Companies, H2 2016 (Contd..1) 22 Products under Investigation by Universities/Institutes, H2 2016 23 Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc, H2 2016 24 Retinitis Pigmentosa (Retinitis) - Pipeline by Allergan Plc, H2 2016 25 Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings Inc, H2 2016 26 Retinitis Pigmentosa (Retinitis) - Pipeline by Amgen Inc, H2 2016 27 Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corp, H2 2016 28 Retinitis Pigmentosa (Retinitis) - Pipeline by Asklepios BioPharmaceutical Inc, H2 2016 29 Retinitis Pigmentosa (Retinitis) - Pipeline by Astellas Pharma Inc, H2 2016 30 Retinitis Pigmentosa (Retinitis) - Pipeline by Caladrius Biosciences Inc, H2 2016 31 Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici SpA, H2 2016 32 Retinitis Pigmentosa (Retinitis) - Pipeline by Genethon SA, H2 2016 33 Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics SA, H2 2016 34 Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional SA, H2 2016 35 Retinitis Pigmentosa (Retinitis) - Pipeline by ID Pharma Co Ltd, H2 2016 36 Retinitis Pigmentosa (Retinitis) - Pipeline by InFlectis BioScience, H2 2016 37 Retinitis Pigmentosa (Retinitis) - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 38 Retinitis Pigmentosa (Retinitis) - Pipeline by M's Science Corp, H2 2016 39 Retinitis Pigmentosa (Retinitis) - Pipeline by MeiraGTx Ltd, H2 2016 40 Retinitis Pigmentosa (Retinitis) - Pipeline by Mimetogen Pharmaceuticals Inc, H2 2016 41 Retinitis Pigmentosa (Retinitis) - Pipeline by Nanovector srl, H2 2016 42 Retinitis Pigmentosa (Retinitis) - Pipeline by Novelion Therapeutics Inc, H2 2016 43 Retinitis Pigmentosa (Retinitis) - Pipeline by RegenxBio Inc, H2 2016 44 Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group Plc, H2 2016 45 Retinitis Pigmentosa (Retinitis) - Pipeline by SanBio Inc, H2 2016 46 Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H2 2016 47 Retinitis Pigmentosa (Retinitis) - Pipeline by Shire Plc, H2 2016 48 Retinitis Pigmentosa (Retinitis) - Pipeline by Spark Therapeutics Inc, H2 2016 49 Retinitis Pigmentosa (Retinitis) - Pipeline by Staidson (Beijing) Biopharmaceuticals Co Ltd, H2 2016 50 Retinitis Pigmentosa (Retinitis) - Pipeline by Sucampo Pharmaceuticals Inc, H2 2016 51 Retinitis Pigmentosa (Retinitis) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 52 Assessment by Monotherapy Products, H2 2016 53 Number of Products by Stage and Target, H2 2016 55 Number of Products by Stage and Mechanism of Action, H2 2016 58 Number of Products by Stage and Route of Administration, H2 2016 60 Number of Products by Stage and Molecule Type, H2 2016 62 Retinitis Pigmentosa (Retinitis) - Dormant Projects, H2 2016 144 Retinitis Pigmentosa (Retinitis) - Dormant Projects (Contd..1), H2 2016 145 Retinitis Pigmentosa (Retinitis) - Discontinued Products, H2 2016 14



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify